Agilent and Healex agree to co-market ChemLaunch for remote access and control of ChemStation and associated instruments
Agilent Technologies and Healex Systems have announced an agreement to co-market Healex's ChemLaunch and Agilent ChemStation.
Agilent and Healex will promote ChemLaunch as a solution for remote access and control of Agilent ChemStation and associated analytical instruments, such as the Agilent 6890 gas chromatograph (GC) and Agilent 1100 series liquid chromatograph (LC).
The alliance is expected to benefit analytical laboratories in a wide range of industries by providing a solution that allows distributed laboratories to improve control and usage of their analytical systems as well as reduce their purchase and support costs for PCs.
Healex Systems's ChemLaunch, introduced in December 2000, was originally developed as a project to help companies face the challenge of managing a large number of Agilent ChemStations and analytical instruments that were distributed throughout sites in several locations.
The instruments were in significant demand but often sat idle because potential users were unaware of their availability and unable to access them remotely.
Software developers at Healex utilised Citrix MetaFrame technology to develop ChemLaunch as a secure internet/intranet-based system, which allows researchers to access Agilent ChemStations from any approved location.
Users can then determine availability status and begin conducting experiments remotely on equipment not in use.
Agilent ChemStation is a family of networked data systems that provides modular software components for instrument control, data acquisition and data management, with the flexibility to meet a lab's present and future requirements.
The ChemStation base software handles applications such as LC, liquid chromatography with mass spectrometry (LC/MS), GC, capillary electrophoresis (CE) and CE/MS, and can be extended with add-on software modules for data organisation and storage, remote control and monitoring, compliance with US FDA 21 CFR Part 11, and validation of analytical methods.
